A_phase_II_trial_of_high-dose_cisplatin_and_dacarbazine._Lack_of_efficacy_of_high-dose,_cisplatin-based_therapy_for_metastatic_melanoma._Cisplatin_and_dacarbazine_are_used_widely_in_the_treatment_of_metastatic_melanoma._To_evaluate_high-dose_cisplatin_and_dacarbazine,_32_patients_with_metastatic_melanoma_were_treated_with_cisplatin_50_mg/m2_and_dacarbazine_350_mg/m2_daily_for_three_days_repeated_at_28-day_intervals._Their_median_age_was_43.5_years_(range,_25_to_73_years),_and_their_median_Karnofsky_performance_status_was_80%_(range,_70%_to_100%)._Measurable_and_evaluable_disease_sites_(number_of_patients)_included_lymph_nodes_(22),_lung_(17),_soft_tissue_(16),_liver_(13),_bone_(seven),_spleen_(four),_adrenal_gland_(three),_skin_(three),_and_other_sites_(five)._Patients_received_a_median_of_two_cycles_of_therapy_(range,_one_to_eight_cycles)._Thirty_patients_were_evaluable_for_response._No_complete_responses_were_observed._Five_patients_had_a_partial_response_(17%;_95%_confidence_interval,_3%_to_30%)_for_16+,_12+,_7,_6.5,_and_3_months._Responding_sites_of_disease_included_lymph_nodes_(five_of_22),_lung_(three_of_17),_and_soft_tissue_(two_of_16)._Hematologic_toxicity_(Grade_greater_than_or_equal_to_3)_included_neutropenia_(16_of_32_patients,_30_of_90_cycles),_thrombocytopenia_(eight_of_32_patients,_12_of_90_cycles),_and_anemia_(five_patients)._Nine_episodes_of_neutropenia_and_fever_were_seen_in_four_patients;_two_had_bacteremia._Nonhematologic_toxicity_(Grade_greater_than_or_equal_to_3)_included_hypotension_(two_patients),_nausea_and_vomiting_(four),_neuropathy_(two),_ototoxicity_(four),_and_hypomagnesemia_(nine)._The_low_objective_response_rate_and_severe_toxicity_of_this_regimen_preclude_its_standard_use_in_patients_with_metastatic_melanoma._A_review_of_cisplatin-based_therapy_in_metastatic_melanoma_suggests_that_there_is_no_dose-response_relationship._The_use_of_high-dose_cisplatin_(greater_than_100_mg/m2)_in_the_treatment_of_metastatic_melanoma_is_not_recommended.